News Releases

Patient enrolment completed in Phase II clinical trial evaluating Allon’s AL-108 in schizophrenia-related cognitive impairmenT

VANCOUVER — December 2, 2008 - Allon Therapeutics Inc. (TSX: NPC) announced today that patient enrolment is complete in a Phase II clinical trial evaluating the safety and efficacy of the Company’s proprietary drug candidate AL-108 in patients with schizophrenia-related cognitive impairment. The... Continue reading →

Allon drugs receive U.S. patent for treatment of neuropathy

VANCOUVER — November 18, 2008 - Allon Therapeutics Inc. (TSX: NPC), announced today that it has been issued a United States patent covering the use of its neuroprotective drugs as potential treatments for peripheral neuropathy, a group of debilitating and painful conditions suffered by millions o... Continue reading →

Allon Therapeutics reviews product development at BIO-Europe 2008

VANCOUVER — November 17, 2008 - Allon Therapeutics Inc. (TSX: NPC), will review progress of its clinical-stage Alzheimer’s disease and preclinical-stage peripheral neuropathy programs November 18 at BIO-Europe 2008 in Mannheim, Germany, the largest European partnering conference for the global bi... Continue reading →

Allon Therapeutics releases Third Quarter operating results

VANCOUVER — November 7, 2008 - Allon Therapeutics Inc. (TSX:NPC) reported today in its Third Quarter 2008 operating results that the Company continues to make progress toward achieving its 2008 milestones, including commencing a Phase IIb clinical trial in Alzheimer’s disease and signing a partne... Continue reading →

Allon granted U.S. patent for new class of drug candidates

VANCOUVER — October 7, 2008 - Allon Therapeutics Inc. (TSX:NPC) announced today that it has been granted a United States patent covering composition, delivery and method of use for new neuroprotective drugs comprised of combinations of peptides from the Company’s two proprietary technology platf... Continue reading →

← Older posts Newer posts →